Administration of tamoxifen for ER+ treatment decreased the recurrence rate by an average of 39%, demonstrating the effectiveness of endocrine therapy in reducing the recurrence of early ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.